title: Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.
abstract: In this report, we show that affinity purified human anti-delta opioid receptor (DOR) autoantibodies from IVIG are specific to DOR and possess agonistic properties displayed by their ability to dramatically decrease forskolin stimulated cAMP accumulation. Anti-DOR autoantibody also caused phosphorylation of the opioid receptor. Anti-DOR autoantibody treatment showed a significant reduction in CXCR4 gene expression as well as surface protein expression. In contrast, anti-DOR autoantibody treatment significantly upregulated CCR5 gene and protein expression. The presence of anti-DOR autoantibodies in IVIG and their potent immunomodulatory activity is further evidence to support the cross-talk between the neuroendocrine and immune systems.
authors.affiliation: Department of Immunobiology, University of Arizona, 1656 E. Mabel Street, PO Box 245221, Tucson, Arizona 85724, USA.
authors.forename: Parvathi
authors.initials: P
authors.lastname: Ranganathan
authors.forename: Hao
authors.initials: H
authors.lastname: Chen
authors.forename: Miranda K
authors.initials: MK
authors.lastname: Adelman
authors.forename: Samuel F
authors.initials: SF
authors.lastname: Schluter
mesh_terms: D000818:Animals; D001773:Blood Cells / Q000187:drug effects / Q000378:metabolism; D016466:CHO Cells; D005576:Colforsin / Q000494:pharmacology; D006224:Cricetinae; D003412:Cricetulus; D000242:Cyclic AMP / Q000378:metabolism; D004347:Drug Interactions; D004983:Ethanolamines / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D005434:Flow Cytometry / Q000379:methods; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology*; D007155:Immunologic Factors / Q000494:pharmacology*; D009292:Narcotic Antagonists; D009294:Narcotics / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D011485:Protein Binding / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D054398:Receptors, CCR4 / Q000235:genetics / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000235:genetics / Q000378:metabolism; D017465:Receptors, Opioid, delta / Q000235:genetics / Q000276:immunology*; D013997:Time Factors; D014162:Transfection / Q000379:methods
chemical_list: C515354:CCR4 protein, human; C527276:CXCR4 protein, human; D004983:Ethanolamines; D005231:Fatty Acids, Unsaturated; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D009292:Narcotic Antagonists; D009294:Narcotics; D012333:RNA, Messenger; D054398:Receptors, CCR4; D019718:Receptors, CXCR4; D017465:Receptors, Opioid, delta; C494000:dipalmitoleoylphosphatidylethanolamine; D005576:Colforsin; D000242:Cyclic AMP